May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
Author Affiliations & Notes
  • T. C. Kreutzer
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • A. H. Wolf
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • D. Kook
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • C. S. Alge-Priglinger
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • A. Hofer
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • R. Strauss
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • C. Haritoglou
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • A. Kampik
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • S. Priglinger
    University Eye Hospital, Ludwig Maximilians University, Munich, Germany
  • Footnotes
    Commercial Relationships T.C. Kreutzer, None; A.H. Wolf, None; D. Kook, None; C.S. Alge-Priglinger, None; A. Hofer, None; R. Strauss, None; C. Haritoglou, None; A. Kampik, None; S. Priglinger, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 301. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. C. Kreutzer, A. H. Wolf, D. Kook, C. S. Alge-Priglinger, A. Hofer, R. Strauss, C. Haritoglou, A. Kampik, S. Priglinger; Intravitreal Bevacizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2007;48(13):301.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To evaluate the effectiveness of intravitreal application of bevacizumab on retinal thickness and visual acuity in eyes with macular oedema following branch retinal vein occlusion (BRVO).

Methods:: After signing the consent form thirtyfour patients with macular edema following BRVO were treated with at least two and up to six intravitreal injections of 1.25mg of bevacizumab in four weeks intervals and followed up for six month. At defined time points two and six weeks, as well at three month and the six month after study inclusion OCT scans and visual acuity scores (Snellen, ETDRS) were collected additionally to thorough clinical evaluation of the eyes.

Results:: Patients presented at a mean age of 69 years (range 44 - 86 years). Mean duration of symptoms from branch retinal vein occlusion was 40 weeks (range 1 - 300 weeks). Visual acuity at baseline showed mean results of 0.79 LogMAR (±0.39) and improved to a mean of 0.46 LogMAR (±0.38) at the six month control visit (P = 0.009). Cases achieved a mean of 45.3 (±19.0) letters on the ETDRS-chart at baseline and improved to a mean of 65.3 (±20.6) letters at the six month control visit (P = 0.003). Retinal thickness as measured by the OCT at baseline was 473µm (±120) and declined to a mean of 326µm (±90) at the six month control visit.

Conclusions:: Intravitreal injections of 1.25mg bevacizumb seems to be an effective treatment for branch retinal vein occlusion and increases visual acuity even in cases with chronic macular oedema.

Keywords: vascular occlusion/vascular occlusive disease • macula/fovea • retinal neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×